Stellar Biotechnologies Presents at Annual 2013 NSF Conference
News Jul 05, 2013
Stellar Biotechnologies, Inc. has announced the presentation of a poster at the Annual 2013 National Science Foundation (NSF) Conference in Baltimore, MD highlighting the Company’s achievements in developing methods related to the sustainable cultivation of the ocean mollusk that is the sole source for Keyhole Limpet Hemocyanin (KLH).
KLH protein is only derived from the Giant Keyhole Limpet (Megathura crenulata), a scarce sea mollusk native to the Pacific Coast waters off California.
The poster titled “Megathura crenulata Post Larval Culture – Bottleneck for a Valuable Medical Resources” was presented by Brandon Lincicum, Stellar’s Executive Director of Aquaculture and Operations.
The presentation recapped innovations that have allowed Stellar to achieve, for the first time in the KLH industry, systems and processes that protect and sustain multiple generations of the Giant Keyhole Limpet in land-based aquaculture.
These accomplishments are critical to supplying enough clinical-quality KLH to meet the future demands of pharmaceutical companies and researchers.
Stellar’s work was partially supported by NSF SBIR Phase I/II, Phase IIB and prestigious Technology Enhancement Commercial Partnership (TECP) funding.
“Stellar now has the world’s only demonstrated aquaculture technology for sustainable growth and cultivation of Megathura crenulata and production of KLH,” said Lincicum. “It was gratifying to present our industry-leading accomplishments at the prestigious NSF conference.”
Protein That Helps Keep Breast Cancer Dormant IdentifiedNews
A protein kinase that stops breast cancer cells growing and spreading has been outlined in new research.READ MORE
Barrier to Liquid Biopsies Overcome with Blood Stabilization TechniqueNews
A new technique that prolongs the lifespan of blood samples could be a breakthrough for liquid biopsy assays.READ MORE
Could New Treatment Strategy Overcome Drug Resistance in Testicular Cancer?News
In a new study, scientists show that a targeted drug blocking the action of a cancer-driving protein can kill testicular cancer cells and, alongside chemotherapy, could reverse drug resistance.READ MORE